Elicio Therapeutics and Angion Enter into Definitive Merger Agreement
17 janv. 2023 05h00 HE
|
Angion Biomedica Corp.
Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technologyLead program of the combined company will...
Angion Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
21 déc. 2022 21h50 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel...
Angion Provides Corporate Update and Reports Second Quarter 2022 Financial Results
15 août 2022 16h05 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel...
Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder Value
25 juil. 2022 16h30 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease
29 juin 2022 16h05 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., June 29, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
Angion Provides Corporate Update and Reports First Quarter 2022 Financial Results
16 mai 2022 16h05 HE
|
Angion Biomedica Corp.
-- Ended the quarter with $73M in cash and cash equivalents sufficient to fund operations well into 2023 UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a...
Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis
16 mai 2022 00h05 HE
|
Angion Biomedica Corp.
-- The FDA has accepted an IND application supporting clinical development of ANG-3070 in IPF -- Phase 1b trial to be initiated to gather tolerability, safety, and pharmacokinetic data in IPF...
Angion Announces Participation in Upcoming Investment Conference
12 mai 2022 16h05 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., May 12, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
Angion Announces Participation in Upcoming Investment Conference
14 avr. 2022 16h05 HE
|
Angion Biomedica Corp.
UNIONDALE, N.Y., April 14, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
Angion Provides Corporate Update and Reports Full Year 2021 Financial Results
30 mars 2022 16h05 HE
|
Angion Biomedica Corp.
-- Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases -- Ended the year with nearly $89M in cash and cash equivalents ...